Preclinical Drug Discovery & Development with Zebrafish
InVivo Biosystems is trusted by pharmaceutical and other biotech partners around the globe to quickly and cost effectively develop human relevant solutions. Using zebrafish, we provide deep insights into preclinical development programs and drug discovery that go beyond the test tube.
Determine if a lead compound ameliorates disease phenotypes or affect important metabolites.
Determine if genes are involved in disease processes and make good targets for further discovery.
Medium throughput screen of compound libraries and biologics (up to BSL2).
Perform acute embryo toxicity testing, targeted hepatotoxicity, neurotoxicity, and cardiotoxiciity analysis.
We perform lifetime monitoring of a large population animals to determine whether compounds and formulations affect lifespan and healthspan.
We uncover whether a compound or formulation has antioxidant properties using a standardized reactive oxygen species exposure assay.
We utilize cutting-edge RNAseq and transcriptomics technology to reveal how compounds impact gene expression by analyzing up or down-regulated genetic pathways.
We investigate the impact of a compound or formulation on mitochondrial function across the lifespan utilizing fluorescent imaging of mitochondrial structures.
We determine the role of the underlying genetics in creating health benefits and investigate the underlying mechanisms involved in pathway.
The InVivo Biosystems Newsletter is delivered to your inbox bi-weekly,
giving you all of the latest company updates, industry news, and more.
An expert in CRISPR genome editing, InVivo Biosystems creates custom genome-edited C. elegans and zebrafish models to enable aging, developmental, and disease studies. Our unique in vivo platforms and technologies bridge the gap between cells and mice.